STD Testing Market by Type (Blood Tests, Lumbar Puncture, Swab Tests), Product Type (Instruments, Reagents & Kits), Test Settings, Indication, End-user - Global Forecast 2024-2030
Description
STD Testing Market by Type (Blood Tests, Lumbar Puncture, Swab Tests), Product Type (Instruments, Reagents & Kits), Test Settings, Indication, End-user - Global Forecast 2024-2030
The STD Testing Market size was estimated at USD 9.44 billion in 2023 and expected to reach USD 9.97 billion in 2024, at a CAGR 5.90% to reach USD 14.11 billion by 2030.
Sexually transmitted disease (STD) testing market comprises various medical examinations used to identify the presence of sexually transmitted infections (STIs). STD testing plays a critical role in ensuring individual health, preventing the spread of STDs, and facilitating timely treatment. The need for STD testing arises when symptoms are apparent and as a preventive health measure, considering that many STDs may remain asymptomatic for prolonged periods. The types of tests conducted vary widely, encompassing blood tests, urine tests, swabs, and physical examinations, each targeting specific infections such as HIV, herpes, chlamydia, gonorrhea, syphilis, and human papillomavirus (HPV). The significant growth factors impacting the STD testing market include increasing awareness about STDs among the general population, governmental and non-governmental efforts to combat the spread of STDs, and advancements in diagnostic technologies. Enhanced accuracy, accessibility, and the declining stigma associated with STD testing have further propelled the market's growth. Additionally, the rising incidence rates of STDs globally necessitate continuous demand for effective and efficient testing solutions. However, the market faces challenges, including social stigma, particularly in conservative and less-developed regions, financial constraints, limited healthcare infrastructure, and lack of awareness. New opportunities in the STD testing market are emerging from integrating digital health platforms with STD testing services, which offer discreet, convenient, and remote solutions for individuals. The development and commercialization of more comprehensive multiplex testing panels, capable of detecting multiple STDs from a single sample, present significant growth venues. Moreover, expanding into underserved regions with high STD prevalence, coupled with public health initiatives and education campaigns, can open new avenues for the STD testing market.
Regional Insights
The Americas, particularly the United States and Canada, represent a developed market with a strong emphasis on innovation and accessibility. In the United States, the market is defined by high consumer awareness and the presence of major companies leading research and development. Recent patents emphasize non-invasive testing methods and rapid results. Canada's market prioritizes accessible healthcare, with significant investments in public health campaigns and testing centers to increase STD awareness and prevention. The STD testing market in South America is progressing steadily, with Brazil carrying potential due to rising STD prevalence, governmental focus on public health campaigns, and improving healthcare facilities are instrumental in the market's expansion. The EMEA region presents a diverse landscape in the STD testing market. European Union countries exhibit a high demand for advanced diagnostic tests, driven by well-established healthcare systems and ongoing research initiatives. The region has witnessed growth in public-private partnerships for developing innovative testing solutions. In contrast, the Middle East focuses on increasing public awareness and breaking cultural barriers to STD testing with investments in educational campaigns and infrastructure. Africa faces unique challenges due to resource constraints while witnessing a rise in international aid and innovative testing solutions tailored to its needs, indicating a growing market for affordable and accessible STD testing. The APAC region is experiencing rapid development in the STD testing market, driven by rapidly expanding healthcare infrastructure, a growing middle-class population, and increased government initiatives toward public health. Countries such as China, India, and Australia are promoting this growth, focusing on awareness campaigns and integrating advanced technologies for diagnostic testing.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the STD Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rising incidence and prevalence of sexually transmitted diseases worldwide
- Increasing awareness about STDs through education campaigns
- Market Restraints
- Issues regarding strict regulatory guidelines for approval of STD testing products
- Market Opportunities
- Ongoing technical advancements in STD disease diagnostics
- Increasing implementation of nationwide screening tests to encourage the adoption of STD testing
- Market Challenges
- Social stigma associated with visiting specialized STD testing clinics
- Market Segmentation Analysis
- Type: Increasing preference for swab tests for STD testing for their non-invasive nature
- Product Type: Need for high-throughput instruments for high-volume testing environments
- Test Settings: Preference for POC tests for their unmatched convenience and speed
- Indication: Rising occurrence of chlamydia and need for sophisticated testing technologies
- End-user: Expanding usage of STD testing at diagnostic centers for quick turnaround time
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the STD Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the STD Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Strategic Alliance Advances Self-Test Solutions for Sexually Transmitted Diseases
Abingdon Health, in collaboration with Devyn's subsidiary 'Find Out From Home,' achieved a 'design freeze' stage for four essential STD tests, including HIV, hepatitis B, hepatitis C, and syphilis. This achievement results from a CDMO contract encompassed within a broader strategic partnership, which is supported by a service-for-equity agreement whereby Abingdon provides ongoing regulatory and technical support while acquiring a substantial minority equity stake in Find Out.
imaware Expands its Portfolio through binx health’s Consumer Division Purchase
imaware Inc. announced the acquisition of Binx Health’s consumer testing division. This move expands Imaware’s presence in the rapidly growing home-health testing market, particularly for sexually transmitted infection (STI) testing, and broadens its service offerings to a more significant number of enterprise clients.
FDA Approves Advanced At-home Chlamydia and Gonorrhea Test
The U.S. Food and Drug Administration (FDA) granted marketing authorization to LetsGetChecked for its Simple 2 Test, marking the innovative over-the-counter (OTC), at-home diagnostic test for chlamydia and gonorrhea. Available to adults over 18, this authorization represents a leap forward in accessible sexual health diagnostics, previously limited to in-clinic sample collection.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the STD Testing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the STD Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accuquik by AdvaCare Pharma, Alpine Biomedicals Pvt. Ltd., ARCpoint Labs, Becton, Dickinson and Company, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., bioMérieux SA, BioReference Health, LLC by OPKO HEALTH, INC., Danaher Corporation, Daye Limited, Everlywell, Inc., F. Hoffmann-La Roche Ltd., Getein Biotech, Inc., Grifols, S.A., Hologic, Inc., JAL Medical by OK Biotech Co. Ltd., Laboratory Corporation of America Holdings, LifeCell, Lorne Laboratories Limited by Calibre Scientific, Meridian Bioscience Inc. by SD Biosensor, Inc., OraSure Technologies, Inc., Personalabs, Qiagen N.V., Quest Diagnostics, Inc., Randox Laboratories Ltd., Seegene Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Viatris Inc., and Wondfo Biotech Co., Ltd..
Market Segmentation & Coverage
This research report categorizes the STD Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- Blood Tests
- Lumbar Puncture
- Swab Tests
- Urine Tests
- Product Type
- Instruments
- Reagents & Kits
- Test Settings
- Laboratory
- Point of Care
- Indication
- Chlamydia
- Genital Herpes
- Gonorrhea
- Hepatitis B
- HIV/AIDS
- Human Papillomavirus
- Syphilis
- End-user
- Diagnostic Centers
- Hospitals & Clinics
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
182 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidence and prevalence of sexually transmitted diseases worldwide
- 5.1.1.2. Increasing awareness about STDs through education campaigns
- 5.1.2. Restraints
- 5.1.2.1. Issues regarding strict regulatory guidelines for approval of STD testing products
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing technical advancements in STD disease diagnostics
- 5.1.3.2. Increasing implementation of nationwide screening tests to encourage the adoption of STD testing
- 5.1.4. Challenges
- 5.1.4.1. Social stigma associated with visiting specialized STD testing clinics
- 5.2. Market Segmentation Analysis
- 5.2.1. Type: Increasing preference for swab tests for STD testing for their non-invasive nature
- 5.2.2. Product Type: Need for high-throughput instruments for high-volume testing environments
- 5.2.3. Test Settings: Preference for POC tests for their unmatched convenience and speed
- 5.2.4. Indication: Rising occurrence of chlamydia and need for sophisticated testing technologies
- 5.2.5. End-user: Expanding usage of STD testing at diagnostic centers for quick turnaround time
- 5.3. Market Trend Analysis
- 5.3.1. Growing popularity of at-home STD testing kits, coupled with a strong foothold of major companies across the Americas region
- 5.3.2. Expanding government awareness initiatives against STDs due to the prevalence of STDs across the APAC region
- 5.3.3. Stringent regulatory frameworks for diagnostic solutions and innovative product offerings for facilitating accessible STD testing across the EMEA region
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. STD Testing Market, by Type
- 6.1. Introduction
- 6.2. Blood Tests
- 6.3. Lumbar Puncture
- 6.4. Swab Tests
- 6.5. Urine Tests
- 7. STD Testing Market, by Product Type
- 7.1. Introduction
- 7.2. Instruments
- 7.3. Reagents & Kits
- 8. STD Testing Market, by Test Settings
- 8.1. Introduction
- 8.2. Laboratory
- 8.3. Point of Care
- 9. STD Testing Market, by Indication
- 9.1. Introduction
- 9.2. Chlamydia
- 9.3. Genital Herpes
- 9.4. Gonorrhea
- 9.5. Hepatitis B
- 9.6. HIV/AIDS
- 9.7. Human Papillomavirus
- 9.8. Syphilis
- 10. STD Testing Market, by End-user
- 10.1. Introduction
- 10.2. Diagnostic Centers
- 10.3. Hospitals & Clinics
- 11. Americas STD Testing Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific STD Testing Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa STD Testing Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2023
- 14.2. FPNV Positioning Matrix, 2023
- 14.3. Competitive Scenario Analysis
- 14.3.1. Strategic Alliance Advances Self-Test Solutions for Sexually Transmitted Diseases
- 14.3.2. imaware Expands its Portfolio through binx health’s Consumer Division Purchase
- 14.3.3. FDA Approves Advanced At-home Chlamydia and Gonorrhea Test
- 14.3.4. British Startup Launches Tampon That Offers STI Screening
- 14.3.5. iHealth Launches Home Collection Kit for STD Testing
- 14.3.6. Aptitude Medical Systems' Innovative Approach to Combat Sexually Transmitted Infections (STIs)
- 14.3.7. LifeCell International Revolutionizes STD and HPV Screening with At-Home Test Kits
- 14.3.8. Breakthrough 20-Minute Test for Gonorrhea and Chlamydia by Linear Diagnostics
- 14.3.9. US BioTek's Innovative At-Home Testing Solutions
- 14.3.10. Visby Medical Achieves FDA Clearance for Advanced Sexual Health Diagnostic Tool
- 14.3.11. Mylab Launches a Range of Rapid Tests for STDs
- 14.3.12. Strategic Partnership between Maternova and MedMira Enhances Global Access to Rapid Diagnostic Tests for Infectious Diseases
- 14.3.13. Innovative Partnership Tackles STI Spike Among Gen Z with At-Home Testing Solutions
- 14.3.14. Meridian Bioscience Joins Forces with SD Biosensor and SJL Partners
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
